The CAIRP (CAndesartan for In-stent Restenosis Prevention) Trial--a multicenter study of AT1-receptor blocker therapy in coronary stenting

Angiotensin II (Ang II) is implicated in the development of in-stent restenosis (ISR). Ang II- and AT1-receptor blockade could possibly reduce ISR. We enrolled 206 patients into a prospective double-blind, placebo-controlled, multicenter randomized trial of candesartan cilexitil 16 mg to test this n...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of invasive cardiology 2008-05, Vol.20 (5), p.205-210
Main Authors: Krämer, Jochen, Ruf, Rainer G, Schmidt, Sibylle, Axthelm, Christoph, Strasser, Ruth, Janssen, Gerhard, Thieme, Torsten, Kusch, Angelika, Waigand, Jürgen, Dietz, Rainer, Gross, C Michael
Format: Article
Language:English
Subjects:
Angiotensin II Type 1 Receptor Blockers - therapeutic use
Benzimidazoles - therapeutic use
Blood Vessel Prosthesis Implantation
Combined Modality Therapy
Coronary Angiography
Coronary Restenosis - drug therapy
Coronary Restenosis - prevention & control
Coronary Restenosis - surgery
Double-Blind Method
Drug-Eluting Stents
Female
Humans
Male
Middle Aged
Placebos
Prospective Studies
Tetrazoles - therapeutic use
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Angiotensin II (Ang II) is implicated in the development of in-stent restenosis (ISR). Ang II- and AT1-receptor blockade could possibly reduce ISR. We enrolled 206 patients into a prospective double-blind, placebo-controlled, multicenter randomized trial of candesartan cilexitil 16 mg to test this notion. Mean lumen diameter (MLD) was the primary objective measured by quantitative coronary angiography and intravascular ultrasound. The Candesartan Group showed a trend towards a larger MLD at follow up without significant differences in the binary ISR rate. In vessels < 2.75 mm, we found a larger MLD in the treatment group after 6 months. This might indicate the potential benefit of AT1-receptor blocker therapy for certain subgroups when percutaneous coronary intervention is performed with bare-metal stent implantation.
ISSN:1557-2501